POM-V Prescription Required Companion Animal

MiPet Benazapet 2.5 mg Tablets for Cats and Dogs

Active ingredient: Benazepril Hydrochloride

Form

Tablet

Species

Cats Dogs

Manufacturer

Elanco Europe Ltd

VMD MA No.

00879/5083

What it's used for

Dogs: Treatment of congestive heart failure. Cats: Reduction of proteinuria associated with chronic kidney disease.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Benazepril Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

MiPet Benazapet 2.5 mg Tablets for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs:
Treatment of congestive heart failure.
Cats:
Reduction of proteinuria associated with chronic kidney disease.

MiPet Benazapet should be given orally once daily, with or without food. The duration
of treatment is unlimited.
MiPet Benazapet 2.5 mg tablets are flavoured and are taken voluntarily by most dogs
and cats.
Dogs:
MiPet Benazapet should be administered orally at a minimum dose of 0.25 mg (range
0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the
following table:
MiPet Benazapet
®
2.5 mgWeight of dog (kg)Standard DoseDouble Dose2.5 – 50.5 tablet1 tablet>5 – 101 tablet2 tablets
The dose may be doubled, still administered once daily, to a minimum dose of 0.5
mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary
surgeon.

Revised: December 2025
MA split from NI Expiry following AN: 02086/2025
Cats:
MiPet Benazapet should be administered orally at a minimum dose of 0.5 mg (range
0.5-1.0) benazepril hydrochloride/kg body weight once daily according to the
following table:
Weight of Cat (kg)MiPet Benazapet
®
2.5 mg2.5 – 51 tablet>5 – 102 tablets

Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal
failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
Do not use during pregnancy or lactation (section 4.7).

In double-blind clinical trials in dogs with congestive heart failure, MiPet Benazapet
was well tolerated with an incidence of adverse reactions lower than observed in
placebo-treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of
fatigue. On rare occasions diarrhoea and anorexia have been reported in dogs.
In cats and dogs with chronic kidney disease, MiPet Benazapet may increase plasma
creatinine concentrations at the start of therapy. A moderate increase in plasma
creatinine concentrations following administration of ACE inhibitors is compatible with
the reduction in glomerular hypertension induced by these agents, and is therefore
not necessarily a reason to stop therapy in the absence of other signs.
MiPet Benazapet may increase food consumption and body weight in cats.
Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare
occasions in cats.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Revised: December 2025
MA split from NI Expiry following AN: 02086/2025

None.

Revised: December 2025
MA split from NI Expiry following AN: 02086/2025

i. Special precautions for use in animals
No evidence of renal toxicity of the veterinary medicinal product has been observed
(in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney
disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts
during therapy.
The efficacy and safety of MiPet Benazapet has not been established in dogs and
cats below 2.5 kg bodyweight.
ii. Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Wash hands after use.
In case of accidental oral ingestion, seek medical advice immediately and show the
label or the package leaflet to the physician.
Pregnant women should take special care to avoid accidental oral exposure because
angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn
child during pregnancy in humans.

In dogs with congestive heart failure, MiPet Benazapet has been given in combination
with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products
without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal
function. The combination of MiPet Benazapet and other anti-hypertensive agents
(e.g. calcium channel blockers, or diuretics), anaesthetics or sedatives
may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or
other medications with a hypotensive effect should be considered with care. Renal
function and signs of hypotension (lethargy, weakness etc) should be monitored
closely and treated as necessary. Interactions with potassium preserving diuretics
like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended
to monitor plasma potassium levels when using MiPet Benazapet in combination with
a potassium sparing diuretic because of the risk of hyperkalaemia.

Do not store above 25 °C.
Store in a dry place.
Each time an unused half tablet is stored, it should be returned to the open blister
space inserted back into the cardboard box and kept in a safe place out of the reach
of children.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.